IOMERVU

Growth

iomeprol injection

NDAINTRA-ARTERIALSOLUTION
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
18/100

Mechanism of Action

X-Ray Contrast Activity

Pharmacologic Class:

Radiographic Contrast Agent

Loss of Exclusivity

LOE Date
Nov 27, 2029
45 months away
Exclusivity Expiry
Nov 27, 2029